Literature DB >> 7836769

Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism.

I A Haagen1, A J Geerars, M R Clark, J G van de Winkel.   

Abstract

Rat mAbs receive considerable interest for immunologic intervention in man. The rat IgG2b isotype has previously been found to be optimally active both in vivo and in vitro. We found that both a rat IgG2b CD3 mAb and a monovalent hybrid rat IgG2b-mouse IgG1 bispecific Ab triggered T cell activation in PBMC. Inhibition analyses with mAb blocking different human IgG Fc receptors (Fc gamma R) showed a dimorphic pattern. In donors expressing an Fc gamma RIIa-R/R131 allotype (previously defined on the basis of interaction with mouse (m) IgG1 as "high responder") anti-Fc gamma RI mAb 197 inhibited rat IgG2b induced T cell mitogenesis almost completely. In Fc gamma RIIa-H/H131 ("low responder" allotype) donors, however, both anti-Fc gamma RI mAb 197 and anti-Fc gamma RII mAb IV.3 were essential for optimal inhibition of mitogenesis. T cell proliferation experiments performed with the use of Fc gamma R-transfected fibroblasts as accessory cells showed the high affinity Fc gamma RIa (CD64) to interact with both rat IgG2b and rat IgG2b-mlgG1 hybrid CD3 mAb. The use of the two types of Fc gamma RIIa (CD32)-transfectants instead showed rat IgG2b CD3 mAb to interact solely with the IIa-H/H131 allotype. Interestingly, rat IgG2b-mlgG1 hybrid mAb did not interact effectively with this low affinity Fc gamma R. This suggests a requirement for only one rat IgG2b H chain for Fc gamma RIa-mediated binding, whereas two identical H chains seem to be necessary for proper interaction with Fc gamma RIIa. Ab-sensitized RBC-rosette experiments performed with the use of a rat IgG2b anti-NIP mAb confirmed the interaction pattern observed with rat CD3 mAb, supporting the phenomena to be isotype-, and not mAb-, dependent. These analyses point to a unique reactivity pattern for rat IgG2b Abs, interacting both with the high affinity Fc gamma RIa in all donors and Fc gamma RIIa of individuals expressing the IIa-H131 allotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836769

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  CD28 is not directly involved in the response of human CD3- CD56+ natural killer cells to lipopolysaccharide: a role for T cells.

Authors:  M R Goodier; M Londei
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

2.  Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases.

Authors:  Naotake Tsuboi; Kenichi Asano; Michael Lauterbach; Tanya N Mayadas
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

3.  The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.

Authors:  R Zeidler; J Mysliwietz; M Csánady; A Walz; I Ziegler; B Schmitt; B Wollenberg; H Lindhofer
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

4.  C-reactive protein (CRP) but not the related pentraxins serum amyloid P and PTX3 inhibits the proliferation and induces apoptosis of the leukemia cell line Mono Mac 6.

Authors:  Wensheng Chen; Darrell Pilling; Richard H Gomer
Journal:  BMC Immunol       Date:  2017-12-04       Impact factor: 3.615

5.  Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia.

Authors:  José Perdomo; Halina H L Leung; Zohra Ahmadi; Feng Yan; James J H Chong; Freda H Passam; Beng H Chong
Journal:  Nat Commun       Date:  2019-03-21       Impact factor: 14.919

Review 6.  The Current Landscape of Antibody-based Therapies in Solid Malignancies.

Authors:  Ashu Shah; Sanchita Rauth; Abhijit Aithal; Sukhwinder Kaur; Koelina Ganguly; Catherine Orzechowski; Grish C Varshney; Maneesh Jain; Surinder K Batra
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

7.  Development of a bispecific immune engager using a recombinant malaria protein.

Authors:  Mie A Nordmaj; Morgan E Roberts; Emilie S Sachse; Robert Dagil; Anne Poder Andersen; Nanna Skeltved; Kaare V Grunddal; Sayit Mahmut Erdoğan; Swati Choudhary; Tobias Gustsavsson; Maj Sofie Ørum-Madsen; Igor Moskalev; Weihua Tian; Zhang Yang; Thomas M Clausen; Thor G Theander; Mads Daugaard; Morten A Nielsen; Ali Salanti
Journal:  Cell Death Dis       Date:  2021-04-06       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.